2024
Contemporary American and European Guidelines for Heart Failure Management JACC: Heart Failure Guideline Comparison
Ostrominski J, DeFilippis E, Bansal K, Riello R, Bozkurt B, Heidenreich P, Vaduganathan M. Contemporary American and European Guidelines for Heart Failure Management JACC: Heart Failure Guideline Comparison. JACC Heart Failure 2024, 12: 810-825. PMID: 38583167, DOI: 10.1016/j.jchf.2024.02.020.Peer-Reviewed Original ResearchConceptsEuropean Society of CardiologySocial determinants of healthDeterminants of healthHealth care disparitiesHeart failureClinical practice recommendationsManagement of heart failureCare disparitiesDevice-based therapiesSocial determinantsEvidence-based pharmacotherapyGroup of patientsHF careSociety of CardiologyClinical careHF preventionPotential downstream implicationsCardiac amyloidosisAmerican CollegeHF risk predictionPractice recommendationsManagement pathwayNoncardiac comorbiditiesRisk predictionHF stages
2017
Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial
Molfenter T, Knudsen HK, Brown R, Jacobson N, Horst J, Van Etten M, Kim JS, Haram E, Collier E, Starr S, Toy A, Madden L. Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. Implementation Science 2017, 12: 135. PMID: 29141653, PMCID: PMC5688699, DOI: 10.1186/s13012-017-0665-x.Peer-Reviewed Original ResearchConceptsOpioid use disorderAddiction treatment fieldPrevalence of OUDSubstantial public health significanceOpioid misuse epidemicExtended-release naltrexonePrimary treatment outcomeEvidence-based pharmacotherapyAddiction treatment workforceSignificant health issuePublic health significanceAddiction treatment providersNaltrexone patientsNon-medical useOUD pharmacotherapyTreatment fieldOUD patientsBuprenorphine patientsPrescription opioidsCluster RCTIntervention periodTreatment outcomesImplementation interventionsOverdose deathsUse disorders
2013
Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study
Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, Potenza MN, Bailey CR, Lin SF, Najafzadeh S, Ropchan J, Henry S, Corsi-Travali S, Carson RE, Huang Y. Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Molecular Psychiatry 2013, 18: 1034-1040. PMID: 23670490, PMCID: PMC3752332, DOI: 10.1038/mp.2013.61.Peer-Reviewed Original ResearchMeSH KeywordsAdultAmidesAnalysis of VarianceArachidonic AcidsBrainEndocannabinoidsEthanolaminesFemaleGlyceridesHumansHydrocortisoneImidazolesLogistic ModelsMalePalmitic AcidsPiperidinesPolyunsaturated AlkamidesPyrazolesRadionuclide ImagingReceptor, Cannabinoid, CB1Stress Disorders, Post-TraumaticYoung AdultConceptsPost-traumatic stress disorderVolume of distributionCB1 receptor availabilityPositron emission tomographyHC groupReceptor availabilityTC groupCannabinoid type 1 receptorStress disorderPositron emission tomography studyEvidence-based pharmacotherapyEtiology of PTSDType 1 receptorEmission tomography studiesAnandamide concentrationsElevated brainPeripheral levelsHealthy controlsCB1 receptorsUntreated individualsPET scansAnimal modelsCortisol levelsLifetime historyEmission tomography
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply